Company intelligence / Profile preview

Tocagen

San Diego, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 3

Overview

Tocagen developed a gene therapy platform targeting cancer, with its lead program for high-grade glioma reaching Phase 3 clinical trials. The pivotal trial failed to meet endpoints in late 2019, leading to layoffs and ultimately a reverse merger with Forte Biosciences in June 2020.

Therapeutic areas: Oncology
Modalities: Gene therapyviral vector-based therapies
Industry: Biotech

Drug pipeline

2 assets

vocimagene amiretrorepvec

Discontinued

Indications: High grade glioma, Glioblastoma multiforme

1 more asset in the full pipeline.

Request access →

Partnerships

Merck KGaA as manufacturing partner for gene therapy drug production

Beyond the preview

Go deeper on Tocagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tocagen.

Explore the full profile